Search Results - "Mroczek, W J"

Comparison of ramipril and enalapril in patients with essential hypertension by Ruddy, M C, Mroczek, W J

“…To compare the clinical safety and efficacy of ramipril, a new long-acting nonsulfhydryl inhibitor of angiotensin-converting enzyme (ACE), with enalapril. A…”
Get more information

Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial by Mroczek, W J

“…The antihypertensive effect of ramipril, a new angiotensin-converting enzyme (ACE) inhibitor, was evaluated and compared to enalapril in a double-blind,…”
Get more information

A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients by Mroczek, W J, Burris, J F, Allenby, K S

“…Amlodipine is a new long-acting calcium antagonist that has a long half-life and appears to be suitable for once-daily administration. A double-blind,…”
Get more information

Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension by Ram, C V, Ames, R P, Applegate, W B, Burris, J F, Davidov, M E, Mroczek, W J

“…In the final analysis of this study at Week 26, 26% of the patients randomized to receive amlodipine attained blood pressure control with amlodipine alone…”
Get more information

A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure by Mroczek, W J, Burris, J F, Klein, J

“…The effects of amlodipine on ambulatory blood pressure were investigated in patients with mild-to-moderate hypertension. Ambulatory recordings showed that…”
Get full text

Pill hoarding and hypercompliance by Burris, J F, Mroczek, W J

Get more information

Comparison of the antihypertensive effects of betaxolol to atenolol by Mroczek, William J., Burris, James F., Hogan, Leo B., Citron, Daniel C., Barker, Allan H., Mcdonald, Robert H.

“…A randomized double-blind multicenter study compared a new oral β 1-adrenergic antagonist, betaxolol 10 to 40 mg (n = 71), with atenolol 25 to 100 mg (n = 75)…”
Get full text

Nitrendipine monotherapy in severe hypertension by Mroczek, W J, Burris, J F

“…Nitrendipine is a new dihydropyridine derivative developed specifically for the treatment of hypertension. Oral nitrendipine was administered to twelve…”
Get more information

Controlled hypertension and life insurance premiums by Burris, J F, Mroczek, W J

Get full text

Safety and tolerability of metoprolol OROS in hypertension treatment by Feliciano, N, Kasarjian, P H, McMillen, J I, Grau, K E, Kessler, C, Stevelman, H B, Hogan, L B, Mroczek, W J, Goldstein, R J, Montoro, R

“…One hundred twenty-six patients with mild to moderate hypertension responsive to beta-adrenergic blocking agents--alone or in combination with other…”
Get more information

Dose-finding study of cilazapril (Inhibace) in patients with uncomplicated essential hypertension by Mroczek, W J, Klein, J, Burris, J F

“…Cilazapril, an angiotensin converting enzyme (ACE) inhibitor with a long half-life, effectively reduced sitting diastolic blood pressure in patients with…”
Get more information

Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension by Burris, J F, Ames, R P, Applegate, W B, Ram, C V, Davidov, M E, Mroczek, W J

“…Amlodipine, a new long-acting dihydropyridine calcium antagonist, was compared with hydrochlorothiazie (HCTZ) in 145 patients with mild to moderate…”
Get more information

Antihypertensive therapy and reduced life-insurance premiums by Mroczek, W J

Get more information

Malignant hypertension: kidneys too good to be extirpated by Mroczek, W J

Get more information

Effectiveness of a new calcium antagonist in severe hypertension by Burris, J F, Santangelo, R P, Mroczek, W J

“…Nitrendipine is a new nifedipine-like calcium antagonist antihypertensive agent. In this study, nitrendipine 5-40 mg orally bid was administered for up to…”
Get more information

Biochemical profiling and the natural history of hypertensive diseases by Mroczek, W J

Get full text

The value of aggressive therapy in the hypertensive patient with azotemia by Mroczek, W J, Davidov, M, Gavrilovich, L, Finnerty, Jr, F A

“…By giving diazoxide intravenously and furosemide orally the diastolic blood pressure was kept under 110 mm Hg and the urinary output over 1 L/day for a 2-week…”
Get full text

Risk factors in bacteriuria by Mroczek, W J

Get more information

Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: Results from a 10-week, double-blind, placebo-controlled, dose-titration study by Neutel, Joel M., Buckalew, Vardaman, Chrysant, Steven G., Mroczek, William J., Ruff, Dennis A., Weber, Michael

“…Background Angiotensin II receptor antagonists are selective blockers of the renin-angiotensin system and represent an alternative to angiotensin-converting…”
Get full text

First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension by Frishman, W H, Burris, J F, Mroczek, W J, Weir, M R, Alemayehu, D, Simon, J S, Chen, S Y, Bryzinski, B S

“…This 30-center, randomized, double-blind, placebo-controlled, parallel-group study was designed to (1) establish that 6.25 mg of hydrochlorothiazide (HCTZ)…”
Get more information